

Listed below are the clinical trials that CRMD has participated in the past:

Wet Age-Related Macular Degeneration

Genentech (HARBOR) – Protocol Number: FVF4579g

FVF4579g: A Phase Iii, Double-Masked, Multicenter, Randomized, Active Treatment–Controlled Study Of The Efficacy And Safety Of 0.5 Mg And 2.0 Mg Ranibizumab Administered Monthly Or On An As Needed Basis (PRN) In Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Regeneron – Protocol Number: VGFT-OD-0605

A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration

Regeneron – Protocol Number: VGFT-OD-0702

A Randomized, Single-Masked, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration

GSK – Protocol Number: MD7108240

A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.

GSK – Protocol Number: MD7111396

An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascular age-related macular degeneration.

Ophthotech – Protocol Number: OPH1000

A Phase I Single Ascending Dose Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Intravitreal Injections Of E10030 (Anti-Pdgf Pegylated Aptamer) Monotherapy And Of E10030 Given In Combination With Lucentis 0.5mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

Ophthotech – Protocol Number: OPH2000

A Phase 1, Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Multiple Intravitreal Injections Of ARC1905 (Anti-C5 Aptamer) Given In Combination Therapy With Multiple Doses Of Lucentis® 0.5 Mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration

LPath – Protocol Number: LT1009-Oph-001

A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEPTM onepcizumab [LT1009] Administered as an Intravitreal Injection to Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Regeneron (CLEAR IT 2) – Protocol Number: VGFT-OD-0508

A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration

Novartis (VERITAS) – Protocol Number: CBPD952E2202

A 24 month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Novartis (DENALI) – Protocol Number: CBPD952A2308

A 24-Month Randomized, Double-Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety And Efficacy Of Verteporfin (Visudyne®) Photodynamic Therapy Administered In Conjunction With Ranibizumab (Lucentis™) Versus Ranibizumab (Lucentis™) Monotherapy In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Occulogix (RHEO) – Protocol Number: RHEO-AMD 01-06

Safety and Effectiveness in a Multicenter, Randomized, Sham-controlled Investigation for Non-exudative Age-Related Macular Degeneration using Rheopheresis

TargeGen – Protocol Number: OPH-TG100801-002

An Open-label, Randomized, Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients With Choroidal Neovascularization Due to Age-Related Macular Degeneration.

TargeGen – Protocol Number: OPH-TG100801-003

An Open-label, Extended Treatment, Safety, Tolerability, and Efficacy of TG100801 in Subjects with Choroidal Neovascularization Due to Age-Related Macular Degeneration Who Have Completed 30-Day Treatment Under Protocol OPH-TG100801-002.

Genaera – Protocol Number: MSI-1256F-301

A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

Eyeteq – Protocol Number: EOP1023

A Phase IV, Open Label, Multi-Center Trial Of Maintenance Intravitreal Injections Of Macugen® (Pegaptanib Sodium) Given Every 6 Weeks For 48 Weeks In Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (Amd) Initially Treated With A Modality Resulting In Maculopathy Improvement

Notal Vision – Protocol Number: HMP-V4

Sensitivity of the Home Macular Perimeter (HMP) in the detection of Choroidal Neovascularization (CNV) secondary to Age Related Macular Degeneration (AMD)

Pfizer (Monet) – Protocol Number: B0451001

Phase II Open Label, Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled, Study Evaluating Pf-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization

Dry Age-Related Macular Degeneration

NEI (AREDS2)

A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Long-Chain Omega-3 Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA] in Age-Related Macular Degeneration.

Sirion – Protocol number: SRFR-001

A Phase II Multicenter, Randomized, Double-Masked, Placebo Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Ophthotech – Protocol Number: OPH2001

A Phase 1 Study To Establish The Safety And Tolerability Of ARC1905 (Anti-C5 Aptamer) In Subjects With Dry Age-Related Macular Degeneration

Geographic Atrophy

Development of Measure for Evaluating Visual Function in Daily Life in Patients with Geographic Atrophy

Vein Occlusion

Regeneron (COPERNICUS) – Protocol Number: VGFT-OD-0819

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Genentech (HORIZON) – Protocol Number: FVF3426g

An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech Sponsored Ranibizumab Study

Genentech (BRAVO) – Protocol Number: FVF4165g

A Phase III, Multicenter, Randomized, Sham Injection–Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects With Macular Edema Secondary To Branch Retinal Vein Occlusion

Genentech (CRUISE) – Protocol Number: FVF4166g

A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects With Macular Edema Secondary To Central Retinal Vein Occlusion

NEI (SCORE)

Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion

Diabetic Macular Edema

Genentech (RISE) – Protocol Number: FVF4170g

A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Genentech (RIDE) – Protocol Number: FVF4168g

A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection -Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Alimera (FAME) – Protocol Number: C-01-05-001

A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema

Pfizer (DEGAS) - Protocol Number: B0451004

A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of Pf-04523655 Versus Laser Therapy

Regeneron (DaVinci) – Protocol Number: VGFT-OD-0706

A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)

DRCR – Protocol D

Evaluation of Vitrectomy for Diabetic Macular Edema

DRCR – Protocol F

Subclinical Diabetic Macular Edema

DRCR – Protocol G

An Observation Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation

Vitreomacular Traction

ThromboGenics – Protocol Number: TG-MV-003

A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel-Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

ThromboGenics – Protocol Number: TG-MV-006

A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Microplasmin for Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion